OSE Immunotherapeutics - OSE-127 encouraging preclinical data in ALL
OSE Immunotherapeutics (OSE) has reported positive preclinical efficacy data for its novel monoclonal antibody therapy OSE-127 in B- and T-cell acute lymphoblastic leukaemia (ALL) disease models. OSE-127 was found to display efficacy signals as a monotherapy in 96% of B- and T-ALL patient-derived xenografts, which included samples from difficult-to-treat relapsed/refractory (r/r) patients. Additionally, details of OSE-127’s unique dual mechanism of action were elucidated, potentially providing differentiation over existing therapies. OSE-127 is being investigated in Phase II studies for the treatment of primary Sjögren’s syndrome and ulcerative colitis and while we acknowledge preclinical results may not translate into clinical utility, the latest data provide encouraging signs for the potential expansion of OSE-127 into additional indications. We continue to value OSE at €398.4m or €21.5 per share.Ose Immunotherapeutics SA, formerly Orphan Synergy Europe Pharma SA, is a France-based company principally engaged in the clinical stage biotechnological sector. The Company develops immunotherapy products against invasive or metastatic late-stage cancers. The Company offers a technology, called Memopi, which helps the immune system to eliminate malignant cells; it re-educates the body's immunological memory so that the immune system (and particularly T cytotoxic cells) attacks tumor cells by increasing the patient's specific cytotoxic T response against their cancer. The Company's main product, Texopi, is a patented combination of ten epitopes, selected and optimized from five tumor associated antigens.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.